We're committed to going the distance with every product at Shire-asking hard questions, exploring new indications, looking for ways to extend proven technologies into new treatments; always with the patients' needs most at heart. The acquisition of New River Pharmaceuticals Inc. ('New River'), for example, didn't just provide Shire with VYVANSE, a next-generation treatment for ADHD; it opened the door to new possibilities associated with CarrierWave technology, which enhances drug metabolism and may well have applications for other medicines. At the same time we're expanding our patient populations with plans to expand our presence in markets outside the US and the proposed launch in the US of INTUNIV, our first non-stimulant ADHD drug.
In the gastrointestinal business unit, we are taking similar strides-leveraging our success with LIALDA, our expertise in ulcerative colitis, and our relationships with gastro-enterologists to explore new options for patients suffering from an entire range of inflammatory bowel diseases. We're currently in the midst of Phase 2 trials for SPD550, a compound we licensed in from Alba Therapeutics Corporation ('Alba') because we believe that it can have important implications for patients suffering from Celiac disease.
Three and a half years ago, when Shire acquired what has since become
known as Shire Human Genetic Therapies, there were only four projects in the
pipeline and there were many questions about this relatively small company's
future. Three deals later-with Amicus Therapeutics, Inc. ('Amicus'), Zymenex
A/S ('Zymenex'), and Jerini AG ('Jerini')- Human Genetic Therapies ('HGT') is
1,000 people strong, with three marketed drugs in its portf
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved